Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration

2019497 citationsJournal Articlehybrid Open Access

Authors

David Liao · Retina Vitreous Associates Medical Group

F Grossi · Apellis Pharmaceuticals (United States)

Delphine El Mehdi · Apellis Pharmaceuticals (United States)

Monica Gerber · Apellis Pharmaceuticals (United States)

David M. Brown · Houston Methodist

Jeffrey S. Heier · Ophthalmic Consultants of Boston

Charles C. Wykoff

Abstract

Local C3 inhibition with pegcetacoplan resulted in statistically significant reductions in the growth of GA compared with sham treatment. Phase 3 studies will define the efficacy and safety profile further.

Topics & Keywords

Retinal Diseases and Treatments Retinal Development and Disorders Retinal Imaging and Analysis

Publication Details

Published in: Ophthalmology

Volume 127, Issue 2, pp. 186-195

DOI: 10.1016/j.ophtha.2019.07.011

Field-Weighted Citation Impact: 38.61

Command Palette

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Authors

Abstract

Topics & Keywords

Publication Details